Učitavanje...
Bortezomib for the treatment of mantle cell lymphoma: an update
Bortezomib is a first in class proteasome inhibitor, initially approved by the US Food and Drug Administration for the treatment of plasma cell myeloma. Bortezomib has been approved for the treatment of relapsed and refractory mantle cell lymphoma (MCL) and, more recently, in the upfront setting as...
Spremljeno u:
| Izdano u: | Ther Adv Hematol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959639/ https://ncbi.nlm.nih.gov/pubmed/27493710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716648566 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|